Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

Summary

The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinson's disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD.

Timeline

Start

2007-12

Primary completion

2008-06

Completion

2008-06

Drugs

Indications